Trials / No Longer Available
No Longer AvailableNCT04225429
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Epizyme, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazemetostat | 800mg/dose taken orally twice every day. |
Timeline
- First posted
- 2020-01-13
- Last updated
- 2024-10-01
Source: ClinicalTrials.gov record NCT04225429. Inclusion in this directory is not an endorsement.